Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 1
Submit an article Journal homepage
4,645
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

Tomoko Hayashia Medical Division, Novartis Pharma K.K., Tokyo, JapanCorrespondence[email protected]
View further author information
,
Hiroki Murayamaa Medical Division, Novartis Pharma K.K., Tokyo, JapanView further author information
,
Yohei Shinfukub Regulatory Office Japan, Novartis Pharma K.K., Tokyo, JapanView further author information
,
Tomoko Taniguchib Regulatory Office Japan, Novartis Pharma K.K., Tokyo, JapanView further author information
,
Isao Tsumiyamac Japan Development, Novartis Pharma K.K., Tokyo, JapanView further author information
&
Naotsugu Oyamaa Medical Division, Novartis Pharma K.K., Tokyo, JapanView further author information
Pages 121-130 | Received 07 Jun 2019, Accepted 23 Oct 2019, Published online: 05 Nov 2019

Related Research Data

Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin
Source: Taylor & Francis
Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.